Praxis Precision Medicines, Inc. (PRAX)
After hours:
| Previous close | 52.88 |
| Open | 52.86 |
| Bid | 54.61 x 200 |
| Ask | 55.12 x 100 |
| Day's range | 51.80 - 56.42 |
| 52-week range | 12.45 - 67.21 |
| Volume | |
| Avg. volume | 203,295 |
| Market cap | 936.417M |
| Beta (5Y monthly) | 2.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -18.69 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 138.60 |
GlobeNewswirePraxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showca
ZacksPraxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April. Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place vi
